Reduced expression of α-L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients
Metrics: PDF 1178 views | HTML 1515 views | ?
Serena Bonin1,*, Alessia Parascandolo2,*, Cinzia Aversa1, Renzo Barbazza1, Nobuo Tsuchida3, Maria Domenica Castellone4, Giorgio Stanta1 and Giancarlo Vecchio5,6,7
1Dipartimento di Scienze Mediche, Università di Trieste-Cattinara, Trieste, Italy
2IRCSS SDN, Naples, Italy
3Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
4Istituto di Endocrinologia e Oncologia Sperimentale G.Salvatore, CNR, Naples, Italy
5Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, Naples, Italy
6Istituto Superiore di Oncologia, Naples, Italy
7Istituto Superiore di Oncologia, Genoa, Italy
Giancarlo Vecchio, email: firstname.lastname@example.org
Keywords: breast cancer; luminal B; lymph node metastasis; α-L-Fucosidase-1; immunohistochemistry
Received: October 06, 2017 Accepted: February 01, 2018 Epub: February 07, 2018 Published: March 16, 2018
Background: The lysosomal enzyme α-L-Fucosidase-1 (FUCA-1) catalyzes the hydrolytic cleavage of terminal fucose residues. FUCA-1 gene is down-regulated in highly aggressive and metastatic human tumors as its inactivation perturbs the fucosylation of proteins involved in cell adhesion, migration and metastases.
Results: Negativity to FUCA-1 was significantly related to the development of later recurrences in breast cancer patients with lymph node involvement at diagnosis. Cancer specific survival of luminal B LN+ patients was influenced by FUCA-1 expression as luminal B LN+ patients with positive expression had a longer cancer specific survival. FUCA-1 mRNA expression was inversely related to cancer stage and lymph node involvement. WB and qPCR analysis of FUCA-1 expression in breast cancer-derived cell lines confirmed an inverse relationship with tumor aggressiveness.
Conclusions: This study shows that, within LN+ breast cancer patients, FUCA-1 is able to identify a sub-set of non recurrent patients characterized by the positive expression of FUCA-1 and that, within luminal B LN+ patients, the expression of FUCA-1 predicts longer cancer specific survival.
Methods: We have analyzed FUCA-1 in 305 breast cancer patients by Immunohistochemistry (IHC), and by qPCR in breast cancer patients and in breast cancer cell lines.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.